Skip to search formSkip to main contentSkip to account menu

N 0923

Known as: N-0923 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
N‐0923 is a non‐ergot, dopaminergic D2 agonist designed to be transdermally available. It has anti‐parkinsonian effects when… 
2001
2001
N-0923 is a non-ergot, dopaminergic D(2) agonist designed to be transdermally available. It has anti-parkinsonian effects when… 
1999
1999
Nicotine, the soluble methyl ester of L-DOPA, and the D(2) agonist N-0923 were given alone and in combination im to five… 
1998
1998
N‐0923, a novel aminotetralin dopamine D2 agonist, was shown to effectively reverse parkinsonian symptoms in nine dopa/agonist… 
Highly Cited
1994
Highly Cited
1994
Certain aminotetralins are known to be potent dopamine D2 receptor agonists. N‐0923, [‐]2‐(N‐propyl‐N‐2‐thienylethylamino)‐5… 
1994
1994
The metabolism of the dopamine D2 agonist N-0923 was investigated by an in vitro isolated liver perfusion. Determining the… 
1993
1993
Using the hippocampal-slice preparation, we attempted to model operant conditioning in vitro by reinforcing pyramidal cell… 
1992
1992
The absorption of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxy-tetralin hydrochloride (1; N-0923…